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Various animal models showed that peroxisome proliferator-
activated receptor (PPAR)γ agonists, when given as a gavage
shortly preceding colitis induction, protect against inﬂamma-
tory bowel disease (IBD). We have examined the effects of
16 days rosiglitazone treatment via the diet prior to dextran
sodium sulphate (DSS)-induced colitis in mice. After 7 days
DSS in the drinking water, rosiglitazone-fed mice had lost sig-
niﬁcantly more weight than control mice. Rosiglitazone-treated
mice had more diarrhea, weight of colon and spleen were in-
creased, and length of colon was decreased. Histology showed
that rosiglitazone-treated mice had more severe colitis, mainly
caused by more ulceration, crypt loss, and edema. Immunoﬂu-
orescence showed a loss of tight junction structure Zonula
Occludens protein 1 (ZO-1) in colons of rosiglitazone-treated
mice as compared to the control mice. Also, serum amyloid
P component (SAP) concentrations in plasma were increased.
However, concentrations of tumor necrosis factor (TNF)-α and
interferon (IFN)-γ in colon homogenates, and TNF-α in spleen
homogenates were signiﬁcantly decreased, whereas interleukin
(IL)-10 in spleen homogenates was increased. Other cytokines
(IL-2, IL-4, IL-6, IL-12p70 and monocyte chemotactic protein
(MCP)-1) and myeloperoxidase (MPO) concentrations showed
no differences. In conclusion, 16 days pretreatment with rosigli-
tazone impaired DSS-induced colitis in mice.
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INTRODUCTION
Peroxisome proliferator-activated receptor (PPAR)γ is a
nuclear hormone receptor, controlling the expression of
numerous genes among others that are involved in in-
ﬂammation (1). PPARγ activation dampens the inﬂam-
matoryresponsebydecreasingNF-κBactivation.PPARγ
is highly expressed in the intestine, suggesting an impor-
tant role in the regulation of the intestinal inﬂammatory
response (2, 3). In line with this assumption, heterozy-
gous PPARγ deﬁcient (+/−) mice are more suscepti-
ble to experimental-induced colitis than wild-type mice
(4, 5). In addition, treatment with PPARγ agonists pro-
tected against colonic inﬂammation in different animal
modelsofinﬂammatoryboweldisease(IBD)(4–12).Also
inhumans,thePPARγ ligandrosiglitazonemayhavepos-
itive effects as suggested by the number of patients that
achieved clinical and endoscopic remission in an open-
label single-arm trial for ulcerative colitis (UC) patients
(13). Unfortunately, this study did not include a control
group, which makes it difﬁcult to draw any ﬁrm conclu-
sions. Yet, these studies together do suggest that PPARγ
activation dampens intestinal inﬂammation. However, in
the studies concerning animals, only the effects of treat-
mentwithPPARγ agonistsattheﬁrstdayofcolitisinduc-
tion(4,11,12),1or2daysbeforecolitisinduction(4,5,7,
8, 10) or after colitis induction (5, 6, 12) were examined.
However, in reality, IBD patients should be treated with
PPARγ agonists such as rosiglitazone for longer periods,
either when applied preventive to avoid the occurrence
of relapses (as a maintenance therapy) or curative during
acute exacerbations. Looking at the current literature, the
latter approach, i.e., 14 days chronic rosiglitazone treat-
ment during chronic trinitrobenzensulfonic acid (TNBS)
colitis induction (6) has been evaluated, whereas the ﬁrst
longer term preventive approach has not been done. Thus,
studies are lacking, which evaluates effects of longer term
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PPARγ agonist treatment before colitis induction. The
aim of the present study was, therefore, to examine the in
vivo effects of longer term preventive treatment with the
PPARγ ligand rosiglitazone on dextran sodium sulphate
(DSS)-induced colitis.
MATERIALS AND METHODS
Experimental Design
All experiments were approved by the Animal Stud-
ies Ethics Committee of the University of Amsterdam,
The Netherlands. Twenty eight-week-old female wild-
type C57BL/6 mice were obtained from Charles River
(Horst, The Netherlands). The mice were housed un-
der standard conditions (AM-III 15 mm, Hope Farms,
Woerden, The Netherlands) and had free access to wa-
ter and food. The mice were randomly assigned to
two groups, which received either control chow (con-
trol group) or control chow enriched with 12 mg/100 g
rosiglitazone (Avandia, GlaxoSmithKline, Brentford,
UK) (rosiglitazone group) for 16 days before colitis in-
duction. Treatments were continued during the week of
colitis induction. Both diets consisted of 21 En% protein,
66 En% carbohydrates, and 14 En% fats. Both diets were
made by Special Diet Services (SDS, Essex, UK) and
irradiated at 25 kGy. Colitis was induced by administra-
tion of 1.5% (w/v) DSS (MW 40 kDa; TdB Consultancy,
Uppsala, Sweden) to the drinking water of the mice for
1 week. Body weights of the mice were recorded every
third day, but were recorded daily in the week of colitis
induction. After 7 days DSS treatment, all mice were
anesthetized with fantanyl-ﬂuanisone-midazolan (FFM)
and sacriﬁced via a cardiac puncture and exsanguina-
tions. Blood was sampled inEDTA tubes (Becton Dickin-
son Vacutainer Systems, Franklin Lakes, NJ) and plasma
was obtained by centrifugation at 2000 g for 20 min at
4◦C and stored at −80◦C until analysis for myeloper-
oxidase (MPO) and serum amyloid P component (SAP)
concentrations. Through a midline incision, the colons
were removed. First, the total length was measured as an
indicator of disease-related colon shortening. In addition,
fecalmaterialwasremovedandcollectedtoscorediarrhea
severity; 0—normal feces, 1—loose stool, 2—watery di-
arrhea,3—slimydiarrhea,littleblood,and4—verysevere
diarrhea.Next,thecolonswereopenedlongitudinallyand
the wet weight of the distal 6 cm was recorded and used
as an index of disease-related intestinal wall thickening.
When the colons were shorter than 6 cm, the entire colon
was removed and weight was recalculated for 6 cm. Sub-
sequently,thecolonsweredividedlongitudinallyintotwo
parts and both were rolled up. For all animals, one role
was used for histological analysis. In ﬁve randomly se-
lected animals from each group, the other role was used
for cytokine detection by means of a cytometric bead
array (CBA) and for immunoﬂuorescence of Zonula Oc-
cludens protein 1 (ZO-1) in the other ﬁve mice from each
group. Besides the colon, for all animals, spleens were
also sampled, weighed, and used for cytokine detection.
All sampled tissues were frozen in liquid nitrogen and
stored at −80◦C until analysis.
Histological Analysis
The longitudinally divided rolled-up parts of the colon,
which were used for routine histology, were directly ﬁxed
in 4% formaldehyde and embedded in parafﬁn. Three
transverse slices (5 µm), taken from each colonic sam-
ple, were stained with hematoxylin-eosin and examined
by light microscopy. Colonic inﬂammation was evalu-
ated in a blind manner by estimating the 1) percentage
of involved area, 2) the amount of follicles, 3) edema, 4)
erosion/ulceration, 5) crypt loss, 6) inﬁltration of poly-
morphonuclear cells, and 7) inﬁltration of mononuclear
cells.Thepercentage ofareainvolved, erosion/ulceration,
and the crypt loss was scored on a scale ranging from 0 to
4 as follows: 0—normal, 1—less than 10%, 2—10–25%,
3—25–50%, and 4—more than 50%. Follicle aggregates
were counted and scored as follows: 0—zero to one fol-
licles, 1—two to three follicles, 2—four to ﬁve follicles,
and 3—six follicles or more. The severity of the other
parameters was scored on a scale from 0 to 3 as follows:
0—absent, 1—weak, 2—moderate, and 3—severe. All
scores on the individual parameters together could results
in a total score ranging from 0 to 24.
Immunoﬂuorescence of Zonula Occludens
Protein-1 (ZO-1)
To examine the distribution of tight junctions, we
stained three colon sections of ﬁve mice per group for
ZO-1. Frozen sections of rolled-up colons were cut
(6 µm), allowed to air dry, ﬁxed with 4% paraformalde-
hyde, and then washed three times with cold PBS. The
sections were blocked with 1:10 normal goat serum and
then incubated for 1 h at room temperature with rabbit
anti-ZO-1 polyclonal antibody (Zymed, San Francisco,
CA). As a negative control, sections were incubated with
PBS-0.1% BSA. Thereafter, sections were washed three
times with cold PBS, incubated with Texas Red con-
jugated goat antirabbit antibody (Jackson, West Grove,
PA) for 50 min at room temperature and washed three
times with PBS. Next, sections were incubated with 4 ,6-
diamino-2-phenyl indole (DAPI) (0.5 mg/mL, Sigma, St.
Journal of Clinical Immunology, Vol. 27, No. 3, 2007ROSIGLITAZONE IMPAIRS COLITIS 277
Louis, MO) for 2 min, washed three times with PBS,
dehydrated in ascending ethanol series, and mounted in
mounting solution (Dako Cytomation, Ely, UK). Distri-
bution of tight junctions was recorded with Metasystems
Image Pro System (Metasystems, Sandhausen, Germany)
mountedonaLeicaDM-REﬂuorescencemicroscope(Le-
ica, Wetzler, Germany). Photomicrographs were recorded
at a 200× magniﬁcation.
Homogenisation and Cytometric Bead Array (CBA)
For analysis of cytokine concentrations, homogenates
were made from colon and spleen samples with a tis-
sue homogenizer in 9 volumes (w/v) Greenberger lysis
buffer (300 mmol/L NaCl, 15 mmol/L Tris, 2 mmol/L
MgCl2, 2 mmol/L Triton X-100 (Sigma, St. Louis, MO),
Pepstatin A, Leupeptin, Aprotinine (Roche, Mannheim,
Germany), all 20 ng/mL; pH 7.4). The tissues were
lysed in the Greenberger lysis buffer for 1 h on ice and
centrifuged for 7 min at 3000 rpm and for 10 min at
14,000 rpm. The supernatant was collected and stored at
−80◦C until cytokine analysis using a cytometric bead ar-
ray. The mouse inﬂammation and Th1/Th2 CBA (Becton
Dickinson Biosciences, San Diego, CA) were used for
colon homogenates and the mouse inﬂammation CBA
in spleen homogenates to determine simultaneously the
concentrations of various cytokines in colon (interleukin
(IL)-2, IL-4, IL-6, IL-10, IL-12p70, monocyte chemotac-
tic protein (MCP)-1, interferon (IFN)-γ and tumor necro-
sis factor (TNF)-α) and spleen (IL-6, IL-10, IL-12p70,
MCP-1 and TNF-α) homogenates according to the in-
structions of the manufacturer. Brieﬂy, 5 µL of sample or
thecytokine standardmixturewas mixed with5µLo fth e
mixed capture beads and 5 µL of the detection antibody-
phycoerythrin(PE)reagentandincubatedatroomtemper-
ature for 2 h in the dark. Two-color ﬂow cytometric anal-
ysis was performed using a FACScan
R  ﬂow cytometer
(Becton Dickinson Immunocytometry Systems (BDIS),
San Jose, CA). Data were acquired and analyzed using
Becton Dickinson CBA software.
Myeloperoxidase (MPO) in Colon Homogenates
and Plasma
To quantify the extent of colonic neutrophil accumu-
lation and systemic neutrophil amounts, MPO concentra-
tions in colon homogenates and EDTA plasma were an-
alyzed by enzyme-linked immunosorbent assay (ELISA)
(HBT, Uden, The Netherlands). In brief, 96 well plates
(Greiner Bio-one, Frickenhausen, Germany) were coated
with 1.5 µg/mL monoclonal MPO antibodies. Immobi-
lized MPO was detected using a speciﬁc biotinylated
rabbit-antihumanMPOantibody,followedbytheaddition
of peroxidase-conjugated streptavidin and tetramethyl-
benzidine (TMB) substrate. All samples of both groups
were analyzed on one plate. The detection limit of the
MPO ELISA was 1.02 ng/mL. The intraassay variation
was less than 7.5%.
Serum Amyloid P Component (SAP) in Plasma
To evaluate the acute phase reaction activity, SAP con-
centrations were analyzed in EDTA plasma by ELISA,
as described in (14). Brieﬂy, 96 well plates (Greiner Bio-
one,Frickenhausen,Germany)werecoatedwith3µg/mL
sheep-antimouseSAP(Calbiochem,SanDiego,CA)anti-
bodies.ImmobilizedSAPwasdetectedusingaspeciﬁcbi-
otinylated rabbit-antimouse SAP antibody (Calbiochem),
followed by the addition of peroxidase-conjugated
streptavidin (Zymed Laboratories, San Francisco, CA)
and TMB substrate (Kirkegaard & Perry Laboratories,
Gaithersburg, MD). All samples of both groups were ana-
lyzed on one plate. The detection limit of the ELISA was
5 ng/mL. The intraassay variation was less than 5%.
Statistical Analysis
All data, except body weights (means ± SEM), are
expressed as dot plots in which the median is indicated.
Differences between the groups were analyzed using
the Mann–Whitney U test. Two analysis of covariance
(ANCOVA) models were used to analyze changes in
body weight. The ﬁrst one evaluated the effects of
rosiglitazone on body weight at the end of 16 days
rosiglitazone treatment using weight at the start of
rosiglitazone treatment (day 0) as covariate and the
second model evaluated the effects of rosiglitazone on
body weight at the end of 7 days DSS treatment (day
23) using weight at the start of DSS treatment (day
16) as covariate. Correlation analyses were performed
using the Spearman correlation test. Values of P < 0.05
were considered statistically signiﬁcant. SPSS 10 for
Macintosh (SPSS, Chicago, IL) was used for the analysis.
RESULTS
Effects of Rosiglitazone on Colitis Severity
During the 16 days, preceding colitis induction,
mice treated with rosiglitazone gained more weight
(15.3±2.7%)thancontrolmice(5.6±2.1%)(P<0.001)
(Fig. 1A). After 7 days DSS, the rosiglitazone-treated
mice had lost signiﬁcantly more weight (−13.5±4.0%
of their initial weight at DSS induction) than the control
mice (−3.8±5.0%) (P<0.001) (Fig. 1B).
Journal of Clinical Immunology, Vol. 27, No. 3, 2007278 RAMAKERS et al.
Fig. 1. Treatment with rosiglitazone increased DSS colitis disease severity. Ten female mice consumed a control diet or the same diet
with 12 mg/100 g rosiglitazone for 16 days prior to DSS colitis induction. Colitis was induced by 1.5% (w/v) DSS in the drinking water
for 7 days. Body weight was recorded prior to colitis induction (A) and after colitis induction as a measure of disease activity (B). Disease
severity was measured 7 days after DSS colitis induction by a diarrhea score (C), colon length (D), colon weight of last 6 cm (E) and
spleen weight (F).
Seven days after DSS-colitis induction, diarrhea of the
mice was scored (Fig. 1C). In agreement with the more
pronounced loss of body weight, the rosiglitazone-treated
mice had more diarrhea (median score 4.0) than control
mice (score 2.5) (P = 0.003).
After sacriﬁcing the mice, the total length of the colon
and the weight of the last 6 cm of the colon were de-
termined and used as indicators of disease-related colon
shortening and intestinal wall-thickening. The weight of
the colon (217 mg) was signiﬁcantly increased and the
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Fig. 2. Treatment with rosiglitazone increased histological score and induced a loss of tight junction protein ZO-1. Ten
female mice consumed a control diet or the same diet with 12 mg/100 g rosiglitazone for 16 days prior to DSS colitis
induction. Colitis was induced by 1.5% (w/v) DSS in the drinking water for 7 days. (A–C) Histological examination
was scored in haematoxylin-eosin (HE) stained sections of colons at 7 days after DSS colitis induction (magniﬁcation
25×). (A) HE staining of representative section of a control mouse and (B) rosiglitazone-treated mouse. (C) Total
histological score of control and rosiglitazone-treated mice. (D–F) Immunolocalization of ZO-1 (red) showed a relative
regular distribution in the colon of control colitis mice (D). ZO-1 is localized in the upper part of the enterocytes,
showing a normal distribution in association with the cellular surface. Although parts of the colon of control colitis
mice showed ZO-1 loss, rosiglitazone treatment (E) led to signiﬁcant more loss of ZO-1. Moreover, the colon tissue
was more disrupted and disorganized, illustrated by an irregular distribution of nuclei (blue). Although tissue sections
of rosiglitazone-treated mice showed parts with a normal distribution of ZO-1 the difference with the control mice was
striking. (F) Negative control staining of a colon section of a control mouse. The histology shown is representative for
all tissue sections studied (magniﬁcation 200×).
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Table I. Different Items of Histology Scores of the Colon of
Rosiglitazone-Treated and Control DSS Colitis Mice
Rosiglitazone Control
(n = 10) (n = 10)
Total score 16.5∗ (12.5–21.0) 12.3 (8.0–16.0)
Area involveda 4.0 (4.0–4.0) 4.0 (3.0–4.0)
Follicle aggregatesb 1.0 (0.0–3.0) 0.0 (0.0–2.0)
Edemab 2.5∗ (1.0–3.0) 1.8 (1.0–2.0)
Ulcerationa 2.0∗ (2.0–3.0) 1.0 (1.0–3.0)
Crypt lossa 3.0∗ (2.0–3.0) 2.0 (1.0–3.0)
Polymorphonuclear cellsb 2.0 (1.5–3.0) 1.8 (0.5–2.5)
Mononuclear cellsb 1.5 (1.0–2.0) 1.5 (1.0–2.0)
aMedian scores (minimum–maximum) on a scale of 0–4; 0 = normal,
1 = less than 10%, 2 = 10–25%, 3 = 25–50%, and 4 = more than
50%.
bMedian scores (minimum–maximum) on a scale of 0–3; 0 = absent,
1 = weak, 2 = moderate, 3 = severe.
∗P < 0.05 versus control group.
length (5.5 cm) of the colon was signiﬁcantly decreased
in the rosiglitazone group (P = 0.005 and P = 0.009,
respectively) as compared to control group (197 mg and
6.5 cm, respectively) (Fig. 1D–E). Also, the weight of the
spleen was signiﬁcantly increased in the rosiglitazone-
treated mice (145 v 93 mg) (P = 0.002) (Fig. 1F).
Colon weight correlated positively with spleen weight
(r = 0.466, P = 0.038) and diarrhea score (r = 0.509,
P = 0.022).
Colonic inﬂammation was also evaluated by histolog-
ical analysis. Figures 2A–B show representative pictures
of the colons from control and rosiglitazone-treated mice.
Colonic inﬂammation in the control mice was mostly
continuous (most severe at the anal side), whereas the
colonic inﬂammation of the rosiglitazone-treated mice
was characterized by skipped-lesions (isolated affected
areas with intervening quite normal mucosa). The total
colitis score was signiﬁcantly increased in the rosiglita-
zonegroup(16.5points)ascomparedtothecontrolgroup
(12.3 points; P = 0.006) (Fig. 2C), which was mainly
caused by an increase in ulceration (P = 0.011), crypt
loss (P = 0.007) and edema (P = 0.043) (Table I). Total
histological score correlated positively with colon weight
(r = 0.514, P = 0.020).
Immunoﬂuorescence showed that ZO-1 appearance in
colons of rosiglitazone-treated mice was less distinct, dif-
fusely localized, and even a loss of ZO-1 protein was ob-
served in several parts of the tissue sections as compared
to control mice (Fig. 2D–F).
Effects of Rosiglitazone on Colon and Spleen Proinﬂam-
matory Cytokine Concentrations
The concentration of different cytokines in colon
and spleen homogenates were analyzed by a CBA to
evaluate the extent of the local immune responses. The
colonic concentrations of TNF-α (P = 0.028) and
IFN-γ (P = 0.009) were decreased in the rosiglitazone
group (Table II). IL-2, IL-4, IL-6, IL-10, IL-12p70,
and MCP-1 concentrations in the colon homogenates
were not signiﬁcantly different between the two groups.
IL-12p70concentrationsincolonhomogenatescorrelated
with TNF-α and IFN-γ (both r = 0.664, P = 0.044)
and TNF-α also correlated with IFN-γ (r = 0.891,
P = 0.001). Furthermore, MCP-1 correlated with
IL-6 (r = 0.685, P = 0.029). Not only in the colon,
but also in the spleen, TNF-α concentrations were
signiﬁcantly (P = 0.028) decreased. However, spleen
IL-10 concentrations were signiﬁcantly (P = 0.013)
increased in the rosiglitazone-treated mice (Table II).
IL-6, IL-12p70, and MCP-1 concentrations in spleen
were not different between the two groups.
Table II. Cytokine Concentrations in Colon and Spleen Homogenates
Colon Spleen
Cytokinea
Rosiglitazone
(n = 5) Control (n = 5)
Rosiglitazone
(n = 10)
Control
(n = 10)
IL-12p70 8.6b (6.6–17.9) 10.0 (9.1–17.2) 4.1 (0.0–5.7) 1.4 (0.0–6.7)
TNF-α 48∗ (38–83) 84 (41–229) 57∗ (30–106) 82 (54–106)
IFN-γ 1.9∗ (1.6–3.0) 8.0 (3.4–37.2) ND ND
MCP-1 867 (455–1131) 477 (391–950) 135 (54–191) 152 (101–342)
IL-10 8.4 (0.0–22.4) 9.6 (7.5–17.8) 3.3∗ (0.0–36.3) 0.0 (0.0–0.0)
IL-6 390 (96–1327) 272 (151–1249) 25 (16–33) 36 (13–290)
IL-4 0.0 (0.0–3.9) 0.0 (0.0–5.0) ND ND
IL-2 2.6 (2.0–3.4) 2.8 (2.1–6.3) ND ND
Note. ND not determined.
aConcentrations in pg/mL.
bMedian (minimum–maximum).
∗P < 0.05 versus control group.
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EffectsofRosiglitazoneonMPOandSAPConcentrations
in Colon Homogenates and/or Plasma
To determine colonic neutrophil accumulation and sys-
temic neutrophil levels, MPO concentrations were an-
alyzed in colon homogenates and plasma. No signiﬁ-
cant differences between the groups were found, neither
in colon homogenates nor in plasma (P = 0.754 and
P = 0.174, respectively) (Fig. 3A–B). MPO concen-
trations in colon homogenates correlated positively with
MCP-1 concentrations in colon homogenates (r = 0.673,
P = 0.033).
Todeterminetheextentoftheacutephaseresponse,we
analyzed plasma SAP concentrations. The SAP concen-
trationoftheplasmaofrosiglitazone-treatedmicewassig-
niﬁcantlyincreasedcomparedtocontrolmice(885ng/mL
versus 196 ng/mL) (P = 0.041) (Fig. 3C). SAP concen-
tration in plasma correlated positively with total histolog-
ical score (r = 0.540, P = 0.014) and diarrhea score
(r = 0.619, P = 0.004).
DISCUSSION
The present study showed that in mice, 16 days pre-
treatment with rosiglitazone in the diet increased colonic
inﬂammation after experimentally DSS-induced colitis.
In contrast with all earlier studies, this is the ﬁrst study
thatshowedadverseeffectsofaPPARγ agonistinacolitis
model. Earlier studies administrated various PPAR ago-
nists (troglitazone, pioglitazone, rosiglitazone, netoglita-
zone) by oral gavage on the ﬁrst day of colitis induction
(4, 12), 1 or 2 days before colitis induction (4, 5, 8, 10), or
after colitis induction (5, 6, 12) until sacriﬁcing the mice.
Each of these studies showed decreased disease activity,
less mortality, and less colonic (Th1) cytokine produc-
tion (4–6, 8, 10, 12). Also, intraperitoneal injection of
pioglitazone—starting at the day of DSS colitis induction
until day 7—showed preventive effects (11). Moreover,
rosiglitazone in the diet, 2 days before colitis induction
protected against acute DSS-colitis (7). The most striking
difference in the design of all these studies as compared
to ours is the time at which PPARγ agonist treatment
was initiated. In our experimental model, we have de-
liberately chosen to test the effects of a PPARγ agonist
in a longer term preventive manner to lower the risk of
relapses. We therefore applied rosiglitazone for 16 days
prior to DSS-induced colitis induction. Only in one other
study, rosiglitazone was added to the diet for a longer
period (9). In that study, Lytle et al. examined the effects
of rosiglitazone treatment in the diet for a period of 12
weeks on the spontaneous development of colitis in IL-10
Fig. 3. Treatment with rosiglitazone did not change MPO concentra-
tions in colon homogenates and plasma, but increased SAP concentra-
tions in plasma. Ten females mice consumed a control diet or the same
diet with 12 mg/100 g rosiglitazone for 16 days prior to DSS colitis
induction. Colitis was induced by 1.5% (w/v) DSS in the drinking water
for 7 days. MPO concentrations were determined in colon homogenates
(A) and in plasma (B) and SAP concentrations were determined in
plasma (C) 7 days after colitis induction.
−/− mice.Incontrasttoourstudy,thisstudyshowedthat
longer term treatment with rosiglitazone slowed down the
onset of spontaneous severe colitis compared to a control
diet. However, rosiglitazone did not prevent colitis devel-
opment and in the end, disease severity was comparable
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between rosiglitazone-treated and control animals. How-
ever, in contrast to our study, rosiglitazone did not worsen
the disease state. It should be realized, however, that the
IL10 −/− model is a different model as compared to
the DSS model. Whereas the IL-10 −/− model depends
on a disregulated immunological response, which results
in spontaneous colitis development, the DSS model is
related to a disruption of epithelial cell barrier function,
which results in acute colitis.
In all studies in which rosiglitazone was administrated
asagavage,dailyintakesvariedbetween1–50mg/kg.Op-
timal (preventive and therapeutic) effects were found at
20 mg/kg, while higher doses had no additional beneﬁcial
effects(4–6,12).Inthetwostudiesinwhichrosiglitazone
was mixed with powdered chow and used in a preven-
tive mode, animals consumed daily about 20 mg/kg (7,
9). It can be calculated that in our study, daily intake
was comparable. Therefore, differences in effects on col-
itis cannot be explained by differences in rosiglitazone
dosage. However, in future studies, a dose response re-
lationship for the longer term preventive (dietary) mode
should be evaluated. Another possibility could be differ-
ences in susceptibility between mice of various genetic
backgrounds. We used C57BL/6 mice whereas other DSS
studies used not only C57BL/6 (5, 8), but also balb/c (10,
11) and Swiss-Webster mice (12). However, these DSS
studies using gavages did not show any differences in
effects between strains. A possible explanation therefore
is that—in contrast to the earlier studies—longer term
rosiglitazone treatment before colitis induction induced
changes in the intestinal barrier, which made the intestine
more susceptible to intestinal damage. In the DSS model,
which depends on intestinal barrier disruption, this in-
creased susceptibility may induce more severe intestinal
damage. This hypothesis however needs to be tested in
future studies, for example, by comparing acute curative
effects of rosiglitazone versus long-term preventive ef-
fects side-by-side in one experiment and by conﬁrming
this data in another model of IBD.
Changes in weight loss, diarrhea, colon weight and
length, spleen weight, histological scores, and plasma
SAP concentration indicated that colitis was more se-
vere in rosiglitazone-treated mice. Although the mice
gained more weight before colitis induction, they also
lost more weight after 7 days DSS colitis. Weight gain
is a known adverse effect of rosiglitazone treatment in
humans (15, 16) and in mice (17), which is also men-
tioned in the instructions of the Avandia tablets. More-
over, also other parameters—diarrhea, colon weight and
length, spleen weight, histological scores, and plasma
SAP concentration—indicate that colitis was more se-
vere in rosiglitazone-treated mice. However, TNF-α lev-
els in colon and spleen and IFN-γ levels in colon were
decreased, and those of IL-10 (an antiinﬂammatory cy-
tokine) in the spleen were increased in the rosiglitazone-
treated mice. Moreover, other cytokines (IL-2, IL-4, IL-
6, IL-12p70, and MCP-1) and MPO concentrations in
colon and/or spleen homogenates and/or plasma showed
no differences. Why these inﬂammatory proteins did not
show an increase as expected from disease severity is
not known. At ﬁrst, the combination of results seems
contradictive, i.e., lower expression of proinﬂammatory
cytokinesinthecolon,nochangeincolonicMPOconcen-
trations,andamoresevereDSS-inducedcolitisphenotype
as evaluated by—among others—weight loss and histo-
logical scores. There are, however, different possibilities
explaining the simultaneous appearance of these charac-
teristics. One possible explanation is that mice were too
sick to produce cytokines at high concentrations, as has
also been found in another study (18). This would imply
thattheacuteinnateinﬂammatoryresponseduringtheﬁrst
days of DSS treatment in the rosiglitazone animals was
so strong that at day 7, when the mice were sacriﬁced,
the local inﬂammatory cells were exhausted. However,
the increased IL-10 concentration does not support this
explanation and suggests an enhanced antiinﬂammatory
immune response. Therefore, a more likely explanation
is that the absence of elevated cytokine concentrations
is caused by the down-regulation of the proinﬂamma-
tory response of intestinal and immune cells by rosigli-
tazone. Other studies with PPARγ agonists also showed
decreased colonic Th1 cytokines (4, 5, 10, 12) and an in-
crease in colonic IL-10 mRNA (5). However, in contrast
to our study, in these earlier studies, colitis was attenu-
ated. We now suggest that the down-regulated immune
response due to long-term rosiglitazone pretreatment will
ultimately result in a situation where there is no adequate
immune response toward the injured epithelium by DSS.
Thiswillenhancethepossibilityofbacterialtranslocation,
consequently leading to more pronounced disease sever-
ity. Also, differences in the distribution of the colonic
damage (continuous from anal toward the small intestine
in control animals and skipped-lesions in rosiglitazone
animals) suggest a different type of colitis/colonic injury
due to rosiglitazone interference. In relation to this latter
explanation, it is more likely that rosiglitazone pretreat-
ment makes the intestinal wall more vulnerable for DSS-
inducedtissueinjury.Althoughinafuturestudyweshould
measuretightjunctiondistributioninrosiglitazone-treated
mice before colitis induction, the striking loss of ZO-
1 protein in rosiglitazone-treated colitis mice as com-
pared to control colitis mice seems suggestive. We do
realize that this does not provide any evidence for the as-
sumption that 16 days rosiglitazone pretreatment makes
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the intestinal wall more susceptible for the DSS-induced
tissue injury; however, with respect to the severe out-
come, we did not want to postpone this knowledge for
too long. Moreover, the increase in spleen weight in the
rosiglitazone-treated animals is of potential concern. It
could simply be a result of the more severe colitis in the
rosiglitazone-treated animals. At this moment, however,
we cannot exclude that it is the result of rosiglitazone
treatment per se.
In conclusion, our results indicate that rosiglitazone
when added to the diet in a preventive approach for a
longer period (16 days) results in a higher susceptibility
for DSS-induced colitis. This ﬁnding is in sharp contrast
to promising results of earlier studies in which PPARγ
agonists were given shortly (i.e., 1 or 2 days) before
experimental colitis induction and longer term dietary
treatment in a spontaneous IL-10 −/− colitis model.
We hypothesize that rosiglitazone pretreatment makes the
intestinal wall more susceptible for DSS-induced tissue
injury ultimately resulting in a more pronounced disease
severity. The phenotypic characteristics suggest that the
PPARγ activationkeepstheinﬂammatoryresponsedamp-
ened despite the higher tissue injury by DSS. Future re-
search is warranted to unravel the mechanism underlying
these unexpected effects and conﬁrm this data in other
IBD models.
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